MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

G. S. Choudhary, S. Al-Harbi, S. Mazumder, B. T. Hill, M. R. Smith, J. Bodo, E. D. Hsi, A. Almasan

Research output: Contribution to journalArticlepeer-review

215 Scopus citations

Fingerprint

Dive into the research topics of 'MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences